

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/21/2012; Page 1

Suggested Formula	Morphine Sulfate 1.0 mg/mL Injection (Solution, 50 mL)	FIN	F 005 005

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Morphine Sulfate, USP	0.050	g				
Sodium Chloride, USP	0.443	g				
Sterile water for injection, USP	40.0	mL				
Sterile water for injection, USP	50.0	mL				
Sulfuric Acid 10% Solution	As required					
Sodium Hydroxide 10% Solution	As required		(8)			

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information	7 (), < 0.
Light sensitive (protect from lig	ght whenever possible): Morphine Sulfate
Controlled substance (adhere a documentation procedures)	o proper handling and Morphine Sulfate
Suggested Preparatory Guidelines	
Non-Sterile Preparat	ion Sterile Preparation
Processing Error / Testing Considerations:	To account for processing error, pH, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 797</i> . Only trained and qualified personnel must prepare this formula.
	All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.
	Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.
	Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.
	Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/21/2012; Page 2

Formula Morphine Surface To Mg Miz Injection (Solution, 50 Miz)

SUGGESTED PREPARATION (for 50 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Morphine Sulfate, USP §	0.050	g			
Sodium Chloride, USP §	0.443	g			
Sterile water for injection, USP §	40.0	mL			
Sterile water for injection, USP §	50.0	mL	®		
Sulfuric Acid 10% Solution §	As required				
Sodium Hydroxide 10% Solution §	As required				

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

	Preparatory Instruction							
	IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique							
1.	Equipment sterilization:							
	Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.							
2.	Powder-liquid preparation:							
	A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (80.0 mL <i>plus</i> processing error adjustments).							
	-Morphine Sulfate -Sodium Chloride							
	Specifications: Continuously mix until all solid particles have completely dissolved.							
	End result: Homogeneous liquid-like solution.							
	Note: Add the next ingredient, once the previous one has been completely added and dissolved.							



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/21/2012; Page 3

Suggested Formula	Morphine Sulfate 1.0 mg/mL Injection (Solution, 50 mL)	FIN	F 005 005

3. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 2A).
- B. Test the pH of the sample. It should lie between 2.5 and 6.5.
- C. If the pH < 2.5, carefully add in a dropwise manner the Sodium Hydroxide 10% Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 10% Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 10% Solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Sodium Hydroxide 10% Solution until the pH of 2.5 to 6.5 is obtained.

IMPORTANT: Do not allow the pH to rise above 6.5.

- D. If the pH > 6.5, carefully add in a dropwise manner the Sulfuric Acid 10% Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Sulfuric Acid 10% Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Sulfuric Acid 10% Solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Sulfuric Acid 10% Solution until the pH of 2.5 to 6.5 is obtained.

IMPORTANT: Do not allow the pH to fall below 2.5.

4. **Filling to volume:**

A. Add additional Sterile water for injection to the above mixture to fill to the required batch size (50.0 mL *plus* processing error adjustments).

Specification: Continuously mix

End result: Homogeneous liquid-like solution

5. Filtering and transferring:

Aseptically filter the solution through a 0.22-µm sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.

6. Filter integrity test:

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

7. Sterility testing:

Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/21/2012; Page 4

Suggested Formula	Morphine Sulfate 1.0 mg/mL Injection (Solution, 50 mL)	FIN	F 005 005
----------------------	--	-----	-----------

SUGGESTED PRESENTATION

GGESTED FR					
Estima Beyond-Use D		14 days, refrigerated, as per USP <797>. BUD based on a successful sterility and endotoxin test result.	Packaş Requirem	-	Sterile, tightly closed, light-resistant injection vials (10 mL).
	1	Use as directed. Do not exceed dose.	prescribed	8	Keep refrigerated. Do not freeze.
	2	Keep out of reach of children.		9	Equilibrate to room temperature before use.
Auxiliary	3	Discard container after use.		10	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
Labels	4	r			Do not use if discolored.
	5	Controlled substance. Dangerous u as directed.	nless used	12	Protect from light.
	6	Do not take with alcohol, sl tranquilizers or other CNS depressar		13	May impair mental and/or physical ability. Use care when operating a car or machinery.
	7	May produce psychological and/o dependence.	r physical	14	Preservative free solution, single use only. Discard any unused portion.
Pharmacist Instructions	Add any auxiliary labels enecific to the API to the dispensing container as deemed necessary				
Patient Instructions	('ontact your pharmacist in the event of adverse reactions				

REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Morphine HP INjection. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties</i> , 2012: 1696.
3.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 6 th <i>Edition</i> . American Pharmaceutical Association; 2009: 637.
4.	Morphine Sulfate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 86.
5.	Morphine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #6276.
6.	Chapter 8: Buffered and Isotonic Solutions. In: Martin, A. <i>Physical Pharmacy, Fourth Edition</i> . Philadelphia, PA: Lipponcott Williams & Wilkins; 1993: 169~189.
7.	Chapter 18: Tonicity, Osmoticity, Osmolaltiy and Osmolarity. In: D.B Troy. <i>Remington: The Science and Practice of Pharmacy</i> , 21st Edition. Baltimore, MD: Lippincott Williams & Wilkins; 2006: 250~265.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

3/21/2012; Page 5

	Aggested Formula Morphine Sulfate 1.0 mg/mL Injection (Solution, 50 mL)	FIN	F 005 005		
8.	8. Morphine Sulfate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 4th Edition</i> . American Pharmaceutical Association; 2009: 391.				
9.	9. Morphine Sulfate (Monograph). <i>United States Pharmacopeia XXXIV / National Formulary</i> 29. Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 3562.				
10.	Morphine. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition.</i> Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2276.				
11.	1. USP <797>. <i>United States Pharmacopeia XXXIV / National Formulary 29.</i> Rockville, MD. US Pharmacopeial Convention, Inc. 2011: 336.				

